Floatz logo

Belzutifan

Observational Study

M.D. Anderson Cancer CenterSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Observational Study cohort.

Asset / SponsorPhaseRating
Abiraterone Acetate
M.D. Anderson Cancer Center
D
LEUPROLIDE
M.D. Anderson Cancer Center
D
PREDNISONE TABLETS
M.D. Anderson Cancer Center
D

Same molecule, other indications

Belzutifan is also rated in:

renal cell carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
Von Hippel Lindau DiseaseDormant
BB
Indicative ·
66 / 100
View asset →
von Hippel-Lindau diseaseDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →